In an article titled “Bevacizumab plus fosbretabulin improves survival in ovarian cancer” (published November 10, 2014,) the headline did not clearly state that drug combination improves progression free survival. It does not improve overall survival.
AT THE 13TH WORLD CONGRESS OF GASTROENTEROLOGY ORLANDO (FRONTLINE MEDICAL NEWS) – Probiotics are ...
The U.S. Supreme Court will not hear oral arguments over President Trump’s controversial travel ...
AT ENDO 2015 San Diego (FRONTLINE MEDICAL NEWS) – Preemptive levothyroxine seems to help ...
